CCHR wants electroshocking children prohibited under child abuse laws
LOS ANGELES, Calif., June 30, 2025 (SEND2PRESS NEWSWIRE) — Child and adolescent psychiatrists have issued a policy statement urging broader access to electroconvulsive therapy (ECT) for children and adolescents despite growing international condemnation of the practice on minors. Both the World Health Organization (WHO) and the United Nations Human Rights Office have called for an outright ban on ECT for children, explicitly stating: 'ECT is not recommended for children, and this should be prohibited through legislation.'[1] The Citizens Commission on Human Rights International (CCHR), a mental health industry watchdog, condemned the statement as 'medically reckless, legally dangerous, and morally indefensible.' CCHR is demanding federal and state lawmakers move urgently to outlaw the electroshocking of children, classifying it as a form of child abuse.
ECT, also known as shock treatment, sends up to 460 volts of electricity through the brain to induce a grand mal seizure. This disruption of the brain's electrical activity alters its structure and function, an especially serious risk to the developing brains of children. Yet child psychiatrists not only call for expanded use of ECT on minors but also oppose 'any efforts—legal, legislative, and otherwise—to block access to ECT.'
Through US Freedom of Information Act requests, CCHR uncovered that children as young as five have been electroshocked. The full scope remains hidden due to the lack of national transparency requirements on ECT usage.
Internationally, some countries have already banned ECT entirely (e.g., Slovenia and Luxembourg). In the U.S., California prohibits it under age 12, and Texas under 16. In Western Australia, ECT on minors under 14 is illegal, with criminal penalties—including jail time—for administering it to children. CCHR was instrumental in helping secure that law, along with state bans in the US.
Disturbingly, a child and adolescent psychiatry group has also called for more research involving ECT on youth, potentially exposing children under age 13 to an unproven and highly invasive procedure. The US Food and Drug Administration (FDA) restricts its use to individuals aged 13 and older for limited diagnoses.
The psychiatry group's statement fails to disclose that brain damage is a known risk of ECT. Yet, the American Psychiatric Association concedes that 'ECT can result in persistent or permanent memory loss.' The joint WHO/UN report adds: 'People being offered ECT should also be made aware of all its risks and potential short- and long-term harmful effects, such as memory loss and brain damage.' [2]
In June 2024, the California Supreme Court ruled that an ECT device manufacturer must warn doctors of the risks of brain damage and permanent memory loss.[3] In 2018, a US District Court judge found there was sufficient evidence for a jury to conclude that an ECT device could cause brain injury.[4]
Neuropathologist Dr. Bennet Omalu—known for discovering chronic traumatic encephalopathy ( brain diseases or damage) in football players—publicly condemned ECT, stating: ' The amounts of electrical energy introduced to the human brain by ECT machines can be nothing but harmful and dangerous…. The patient who receives ECT therapy will manifest permanent and cumulative brain injury, which can be progressive over time and result in chronic encephalopathies and brain degeneration.' [5]
Despite pediatric psychiatry's claim that ECT is 'safe and effective,' the FDA has never required manufacturers to prove ECT's safety or efficacy through clinical trials.[6] Internationally renowned researcher Prof. John Read reports that only 11 placebo-controlled trials of ECT have ever been conducted—all prior to 1985, and all deeply flawed. 'None found any benefit beyond the end of treatment,' he stated. Further, children's developing brains are 'particularly susceptible to the memory loss caused by ECT.' [7]
Legal precedent exists for holding professionals and psychiatric facilities accountable for misleading parents about the safety and nature of treatment. In June 2024, an Arizona jury awarded $2.5 million in punitive damages to the family of a teen girl who suffered coercion and abuse at a troubled teen treatment facility. They successfully argued that they were misled by marketing materials portraying the program as therapeutic and safe, when it was abusive.[8]
CCHR says that this same legal framework must apply to misleading promotion of ECT's benefits to desperate parents. Failing to disclose the full risks of ECT should be subject to the same scrutiny and liability as cases in the troubled teen treatment industry.
CCHR asserts that electroshocking should not only be banned nationwide, but if administered to children, should be held accountable under child abuse laws.
Jan Eastgate, president of CCHR International, stated, 'The electroshocking of children is without moral or scientific justification and should be indefensible under the law. As international bodies condemn it, and legal rulings establish precedent for holding programs accountable for misleading parents, the U.S. must act. We urge lawmakers at all levels to ban ECT, especially on minors, and define it as a form of child abuse.'
CCHR, which was established in 1969 by the Church of Scientology and professor of psychiatry, Dr. Thomas Szasz, recommends parents watch its documentary, Therapy or Torture: The Truth About Electroshock, with expert opinions about how ECT damages minds.
To learn more, visit: https://www.cchrint.org/2025/06/27/despite-calls-for-ban-us-child-psychiatry-pushes-electroshock/
Sources:
[1] World Health Organization, OHCHR, 'Guidance on Mental Health, Human Rights and Legislation,' pp. 58 & 59
[2] https://www.psychologytoday.com/us/blog/psychiatry-through-the-looking-glass/202311/is-it-time-to-ban-electroconvulsive-therapy-for
[3] https://www.wisnerbaum.com/blog/2024/june/wisner-baum-prevails-in-landmark-win-for-patient/
[4] 'ECT Litigation Update: Are Patients Being Warned of Brain Damage Risk?' MAD, 13 June 2019
[5] https://www.wisnerbaum.com/defective-medical-device-injuries/ect/
[6] https://www.wisnerbaum.com/defective-medical-device-injuries/ect/; https://www.cnet.com/health/fda-approved-vs-fda-cleared-whats-the-difference/
[7] https://www.psychologytoday.com/us/blog/psychiatry-through-the-looking-glass/202311/is-it-time-to-ban-electroconvulsive-therapy-for
[8] https://www.reuters.com/legal/legalindustry/column-troubled-teen-industry-scrutiny-builds-litigation-follows-2024-07-12/; https://www.azcentral.com/story/news/local/arizona-education/2024/07/19/spring-ridge-academy-students-arizona-describe-harsh-treatment-after-lawsuit/74461275007/
MULTIMEDIA:
Image link for media: https://www.Send2Press.com/300dpi/25-0630-s2p-cchr-ect-300dpi.jpg
Image caption: Through US Freedom of Information Act requests, CCHR uncovered that children as young as five have been electroshocked. The full scope remains hidden due to the lack of national transparency requirements on ECT usage.
NEWS SOURCE: Citizens Commission on Human Rights
Keywords: AP, ban ECT, child abuse laws, ECT usage, Citizens Commission on Human Rights, CCHR International, electroshock, Jan Eastgate, LOS ANGELES, Calif.
This press release was issued on behalf of the news source (Citizens Commission on Human Rights) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P127282 APNF0325A
To view the original version, visit: https://www.send2press.com/wire/cchr-wants-electroshocking-children-prohibited-under-child-abuse-laws/
© 2025 Send2Press® Newswire, a press release distribution service, Calif., USA.
RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT.
Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Research Says This Way Of Eating May Impact Your Fertility—Doctors Reveal The Truth
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Time-restricted eating (TRE) is having a moment in the sun, to say the least. The eating method—which involves consuming all your daily calories within a set number of hours—can help manage weight, but it may impact another unexpected aspect of your health: your fertility. New research has shown that TRE, a form of intermittent fasting (IF), may improve fertility for those with polycystic ovary syndrome (PCOS). A 2025 review in Metabolism Open examined three studies to determine the relationship between IF, fertility, and PCOS and found that IF helped those with PCOS achieve more predictable ovulation schedules, which can increase the likelihood of pregnancy. Plus, since fasting can help with weight loss, it can potentially improve fertility for those who are obese and may have hypertension and high cholesterol, which can negatively affect fertility, says Joshua Hurwitz, MD, an OB-GYN and reproductive endocrinologist at Illume Fertility in Connecticut. However, fasting can also lead to nutritional deficiencies, which may disrupt one's hormonal balance and decrease egg quality, according to a 2024 study in Cureus Journal of Medical Science that looked at the association between nutritional deficiencies and subfertility. "Human health should be optimal going into pregnancy, and that can be hard to achieve when you are in a caloric deficit,' says Brittany Brown, RD, the founder of Feeding Babies, Nourishing Souls in Nova Scotia, Canada. So, what's the real correlation between fasting and fertility? Experts weigh in on TRE and how it can affect your chances of conceiving. Meet the experts: Joshua Hurwitz, MD, is a board-certified OB-GYN and reproductive endocrinologist and partner at Illume Fertility in Connecticut. Brittany Brown, RD, is the founder of Feeding Babies, Nourishing Souls in Nova Scotia, Canada. Suzanna Chatterjee, MD, is an OB-GYN based in Russellville, Arkansas. Eve Feinberg, MD, is a reproductive endocrinology and infertility specialist at Northwestern Medicine. Mel Spinella, RD, is a New York-based dietitian specializing in fertility and pregnancy nutrition and the founder of Well by Mel Nutrition. A 2023 study in Free Radical Biology and Medicine looked at older mice to see how intermittent fasting impacts reproduction, and found that one month of fasting every other day improved the quality of developing eggs. The fasting lowered the amount of free radicals, molecules that can interfere with cellular processes, including cell division and reproduction, says Brown. Still, Brown points out that this study was done in mice, and there's not enough evidence yet to claim that fasting could have the same effect on humans. 'Future research will hopefully uncover how this works, but for now, we need more data before making recommendations," she says. A 2021 study in the Journal of Translational Medicine looked at 15 women between the ages of 18 and 31 who didn't ovulate. They participated in time-restricted feeding for five weeks, and afterward, 11 of the 15 participants experienced improved menstrual regularity. Many people with PCOS produce high levels of insulin, which can lead to excess male hormones in the body (such as testosterone), preventing ovulation, Suzanna Chatterjee, MD, an OB-GYN based in Russellville, Arkansas explains. Eating stimulates insulin, so with fewer meal times, those with PCOS could experience fewer spikes of insulin, which could help manage those excess hormones. TRE may help restore ovulation and improve fertility outcomes without the need for medication for those with PCOS, adds Eve Feinberg, MD, a reproductive endocrinology and infertility specialist at Northwestern Medicine. Still, fasting won't help everyone with PCOS—in the aforementioned study, four of the 15 women with the condition didn't experience better menstrual regularity. So, more research is needed on the connection between PCOS and fasting. Those with obesity are predisposed to have conditions such as hypertension, high cholesterol, and diabetes, which can 'impair natural fertility, as well as lower the success rates of fertility treatment,' says Dr. Hurwitz. 'Even a modest weight loss of 5 to 10 percent can improve ovulation and hormone balance.' Still, weight loss is only one piece of the puzzle. 'Not everyone who is overweight will have trouble conceiving,' and vice versa, he adds. Plus, studies on TRE's effectiveness as a weight loss tool are conflicting. A 2021 study in Nutrition & Diabetes, which followed 78 men and women with obesity, found subjects had 'meaningful weight loss' after following a TRE plan for eight weeks. But a 2023 study of 547 adults over six months in the Journal of the American Heart Association found that TRE did not help subjects lose weight. So, more research is needed. Experts say those with PCOS and those who are obese may benefit from TRE. But for the general population, there are other better ways to improve one's fertility, such as exercising and eating healthy, balanced meals. 'Eating enough, especially nutrient-dense foods throughout the day, is essential for a healthy menstrual cycle,' as well as ovulation, says Mel Spinella, RD, a New York-based dietitian specializing in fertility and pregnancy nutrition and the founder of Well by Mel Nutrition. Brown also advocates for a more natural, eat-when-you're-hungry approach to mealtimes for those who are actively trying to conceive—even for those with PCOS—and particularly once pregnancy is possible or confirmed. 'Reliable and consistent energy intake is essential for reproductive health, especially in the early moments of pregnancy,' she says. She says that her female clients generally find more success conceiving when they follow less restrictive diets that focus on consuming healthy foods. Plus, the research on fasting and fertility is still in the early phases. 'Ultimately, there is a need for large-scale, long-term randomized control trials to truly understand the long-term impacts of TRE on fertility,' Spinella says. When it comes to intermittent fasting, there are a ton of different schedules breaking down when to eat, from the more flexible 14:10 (14 hours of fasting and 10 hours of eating), to the more restrictive 20:4 plan (20 hours of fasting and four hours of eating). Brown says intense schedules like 20:4 can make it difficult to meet daily nutrient needs, which are essential before getting pregnant. Meanwhile, a 12:12 approach is more flexible and easier to follow for success. For instance, eating only between 7 a.m. and 7 p.m. might naturally reduce late-night snacking on ultra-processed foods without being overly rigid. However, Dr. Chatterjee recommends following a 16:8 schedule, particularly for women with PCOS who are hoping to regulate their cycle. Before beginning any fasting schedule, it's always recommended that you check in with your medical provider to see what they think, Dr. Hurwitz says. At the end of the day, everyone is different and 'there's no one-size-fits-all answer,' to how your body will feel during your fertility journey, Brown says. The way you eat is totally up to you and what will make your body feel best. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Yahoo
an hour ago
- Yahoo
Protein Expression Market to Reach $5 Billion by 2032, Growing at a CAGR of 7.6% from 2025, Says Meticulous Research®
Market Growth Driven by Rising Biopharmaceutical Demand, Recombinant Protein Development, and Government Life Science Research Funding REDDING, Calif., June 30, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Protein Expression Market by System (Mammalian [CHO, HEK 293], Non-mammalian [Bacterial, Insect, Yeast]), Offering (Kits & Reagents, Vectors, Competent Cells, Services), Application (Industrial, Therapeutic, Research), and End User—Global Forecast to 2032", the Protein Expression market is projected to reach $5.0 billion by 2032, growing at a robust CAGR of 7.6% during the forecast period from 2025. The significant growth of the protein expression market is driven by the rapidly expanding biopharmaceutical sector, increasing demand for recombinant proteins across therapeutic and research applications, and substantial government initiatives supporting life science research and development. The market's expansion is fueled by the growing adoption of biosimilars in oncology and autoimmune diseases, emerging opportunities in underpenetrated economies, and the critical need for advanced protein synthesis technologies across pharmaceutical research, biotechnology development, and industrial applications. The industry is experiencing transformational growth through advanced mammalian cell expression systems, innovative recombinant protein technologies, and specialized solutions for therapeutic protein production. Leading companies are investing heavily in contract research organization partnerships while expanding manufacturing capabilities to meet the surging demand for biopharmaceuticals and developing customized protein expression platforms for diverse research and industrial applications. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Advanced Protein Synthesis Technologies The protein expression market represents a critical evolution in biopharmaceutical development and biotechnology research. As the healthcare industry faces increasing demand for personalized medicine and novel therapeutic proteins, protein expression systems offer comprehensive platforms that address the growing complexity of recombinant protein production, biosimilar development, and advanced research applications across therapeutic and industrial sectors. Market leaders are investing substantially in mammalian cell expression technologies, advanced recombinant DNA systems, and sustainable protein production methods, establishing manufacturing capabilities that can deliver high-yield, high-quality protein synthesis solutions for pharmaceutical companies, biotechnology firms, and academic research institutions. This technological advancement is making sophisticated protein expression systems increasingly accessible to emerging biopharmaceutical companies while delivering enterprise-grade performance and comprehensive regulatory compliance capabilities. Dynamic Growth Across Key Market Segments Based on system type, the Mammalian Cell Expression System segment dominates the market in 2025, capturing the largest share due to their low risk of cross-contamination, elimination of post-translational modification requirements, and wider acceptance for therapeutic applications. Mammalian systems, particularly CHO (Chinese Hamster Ovary) and HEK 293 (Human Embryonic Kidney) cells, provide superior protein folding capabilities and native glycosylation patterns essential for therapeutic protein production, making them indispensable for biopharmaceutical manufacturing and clinical research applications. Based on products and services, the Reagents segment is expected to dominate the market in 2025, reflecting their frequent utilization across research, therapeutic development, and industrial protein production processes. The widespread adoption of specialized reagents for protein expression, purification, and analysis drives consistent demand across all end-user segments. Based on application, the Research segment is projected to register the highest CAGR during the forecast period, driven by expanding R&D expenditure, emergence of new disease targets, and increasing focus on pharma-academic collaborations for advanced protein research and drug discovery initiatives. Based on end-user, the Contract Research Organizations (CROs) segment is expected to exhibit the highest CAGR, reflecting the growing trend of pharmaceutical and biotechnology companies outsourcing protein expression services to specialized providers, supported by government initiatives expanding research activities and cost-optimization strategies in drug development. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents exceptional growth opportunities through biosimilar development expansion, emerging economy penetration, and advancement of specialized expression systems for complex therapeutic proteins. Companies are discovering new revenue streams through contract manufacturing services, customized expression platforms, and comprehensive protein production ecosystems while establishing advanced capabilities for large-scale biopharmaceutical manufacturing. Key market drivers include: Expanding Biopharmaceutical Market: Rapid growth in biologics development, biosimilar production, and personalized medicine creating unprecedented demand for scalable, high-quality protein expression systems across therapeutic applications Rising Recombinant Protein Demand: Increasing adoption of recombinant proteins in therapeutics, vaccines, and industrial applications due to advantages including reduced immune reaction risk, elimination of protein contaminants, and shorter production lead times Government Research Funding: Substantial public and private investment in life science research, biotechnology development, and healthcare innovation driving demand for advanced protein expression technologies in academic and research institutions Biosimilar Market Growth: Significant expansion of biosimilar therapeutics in oncology, autoimmune diseases, and rare conditions, supported by favorable regulatory frameworks and cost advantages compared to originator biologics Emerging Economy Opportunities: Rapid biopharmaceutical industry development in China, India, and other emerging markets creating substantial demand for protein expression systems and contract research services Contract Research Expansion: Growing trend of pharmaceutical companies outsourcing protein expression services to specialized CROs for cost optimization, risk mitigation, and access to advanced technologies Regional Market Leadership and Emerging Growth Asia-Pacific emerges as the fastest-growing region during the forecast period, driven by substantial investments in life science research across China and India, growing preference for recombinant technology advantages, and expanding biopharmaceutical manufacturing capabilities. The region benefits from increasing government initiatives supporting biosimilar development, rising pharmaceutical R&D expenditure, and growing demand for biologics across diverse therapeutic areas. Asia-Pacific's rapid growth is further propelled by the development of multinational clinical centers, accelerated approval processes for specialty medicines, and introduction of Marketing Authorization Holder (MAH) frameworks enabling efficient biosimilar commercialization. The region's emerging economies offer significant advantages including infrastructure development investments, competitive labor costs, improving adherence to global manufacturing standards, and increasing regulatory oversight supporting international market access. North America represents a substantial established market supported by mature biopharmaceutical industries, comprehensive regulatory frameworks, and concentration of leading pharmaceutical and biotechnology companies requiring advanced protein expression technologies. The region's robust research infrastructure creates significant opportunities for specialized protein expression solutions and contract research services. Europe maintains strong market presence driven by established biopharmaceutical industries, comprehensive regulatory standards, and emphasis on innovative therapeutic development. The region's diverse biotechnology sectors, including biosimilar development and specialized therapeutics, create substantial demand for advanced protein expression technologies. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global protein expression market features a sophisticated competitive ecosystem comprising established biotechnology leaders, specialized protein expression technology providers, and innovative contract research organizations. This diverse landscape fosters rapid technological advancement and comprehensive solution development across therapeutic, research, and industrial applications. Industry leaders are implementing integrated protein expression platforms that combine advanced mammalian cell systems, specialized reagents, and comprehensive service offerings. Companies are pursuing strategic partnerships with pharmaceutical companies and academic institutions while addressing evolving regulatory requirements across diverse therapeutic applications and international markets. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global protein expression market include Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Takara Holdings Inc. (Japan), GenScript Biotech Corporation (U.S.), Qiagen N.V. (Germany), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), and BECTON, DICKINSON AND COMPANY (U.S.). Latest Industry Developments Recent market developments reflecting industry innovation include: Biosimilar Manufacturing Expansion: Major biopharmaceutical companies expanding manufacturing facilities to meet growing biosimilar demand, including strategic partnerships such as Biocon Ltd. and Mylan N.V.'s biosimilar business combination creating larger-scale production capabilities Contract Research Organization Growth: Rapid expansion of CRO services in emerging economies, driven by pharmaceutical companies' increasing focus on outsourcing protein expression services for cost optimization and risk mitigation Advanced Expression System Development: Investment in next-generation mammalian cell expression technologies offering enhanced protein yields, improved quality control, and streamlined production processes for complex therapeutic proteins Emerging Market Penetration: Strategic expansion into underpenetrated markets across Asia-Pacific and Latin America, capitalizing on growing biopharmaceutical demand, increasing aging populations, and rising disposable income supporting healthcare access Academia-Pharma Collaboration: Increasing partnerships between pharmaceutical companies and academic research institutions for advanced protein research, drug discovery, and therapeutic development leveraging specialized expression technologies Related Reports: DNA Sequencing Market Forecast: Next-Generation Sequencing Technologies Analysis Through 2032 Protein Assays Market Analysis: Technology Analysis Through 2032 Digital Therapeutics Market: Software-Based Therapeutic Applications Analysis Through 2031 About Meticulous Research We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- sales@ Our Website: with us on LinkedIn- Source: Logo: View original content: SOURCE Meticulous Market Research Pvt. Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Whole Genome Sequencing Market to Reach $8.35 Billion by 2032, Growing at a CAGR of 15.4% from 2025, Says Meticulous Research®
Market Growth Driven by Declining Sequencing Costs, Rising Prevalence of Genetic Disorders, Expanding Clinical Applications, and Technological Advancements in Precision Medicine REDDING, Calif., June 30, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Whole Genome Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Library Preparation, DNA Extraction) Sequencing Type (Large, Small, Phased), Technology (SBS, SMRT, Nanopore, Nanoball) Application, End User – Global Forecast to 2032", the Whole Genome Sequencing market is projected to reach $8.35 billion by 2032, growing at a robust CAGR of 15.4% during the forecast period from 2025 to 2032. The growth of the whole genome sequencing market is driven by declining costs of sequencing, increasing prevalence of cancer and genetic disorders, growing utilization of whole genome sequencing in disease diagnostics and precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory and reimbursement scenarios, rising healthcare expenditures, increasing funding for research activities, growing need for early detection and prevention of diseases, technological advancements in sequencing products, and government initiatives promoting the use of sequencing in clinical and research applications. The industry is experiencing revolutionary transformation through sophisticated next-generation sequencing technology integration, artificial intelligence adoption in genomic analysis, and development of comprehensive bioinformatics solutions. Leading companies are embracing precision medicine applications while expanding into emerging markets and developing innovative value-added services for healthcare providers and research institutions worldwide. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Advanced Genomic Technologies The whole genome sequencing market represents a paradigm shift in personalized healthcare and precision medicine optimization. As healthcare providers increasingly prioritize individualized treatment approaches while seeking comprehensive genomic insights, whole genome sequencing offers a revolutionary solution that addresses the growing demand for accurate, cost-effective, and clinically actionable genetic testing. Market leaders are investing heavily in next-generation sequencing technologies and bioinformatics capabilities, establishing genomic analysis infrastructure that can deliver scalable, high-resolution genetic insights. This technological advancement is making sophisticated genomic analysis increasingly accessible while delivering superior diagnostic accuracy and therapeutic guidance benefits. Dynamic Growth Across Key Market Segments Based on offering, the Consumables segment dominates the market in 2025, capturing approximately 70% of the total market share due to recurring use of consumables, continuous advancements in reagents and target enrichment protocols, and growing adoption of whole genome sequencing in clinical settings driving demand for consumables. Additionally, many companies are focusing on both organic and inorganic strategies to enhance their consumable offerings. Based on sequencing type, the Large Whole Genome Sequencing segment leads the market with 76% market share, attributed to high resolution and base-by-base analysis capabilities enabling comprehensive genome sequencing for population-level studies. This segment benefits from increasing use in tumor analysis, disease research, animal and plant breeding selection, and identification of common genetic variations. Based on technology, the Sequencing by Synthesis segment accounts for approximately 56.5% of the market in 2025, attributed to high adoption due to superior accuracy and capability to support both paired-end and single-read libraries, offering high-resolution genome sequencing capabilities. Based on application, the Research Applications segment dominates the market, driven by increasing use of whole genome sequencing to identify novel drug targets, rising demand for gene-based medicines, growing investments in drug research and development, and expansion of research programs focused on personalized medicine. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents extraordinary growth opportunities through precision medicine integration, expanding clinical applications, and development of comprehensive bioinformatics solutions. Companies are discovering new revenue streams through advanced genomic analytics capabilities and integrated diagnostic platforms while establishing comprehensive genetic testing ecosystems. Key market drivers include: Declining Sequencing Costs: Dramatic reduction in whole genome sequencing costs making genomic analysis increasingly accessible for clinical and research applications across diverse healthcare settings Rising Disease Prevalence: Increasing prevalence of cancer and genetic disorders driving demand for comprehensive genomic analysis to support diagnosis, treatment selection, and therapeutic monitoring Precision Medicine Expansion: Growing utilization of whole genome sequencing in disease diagnostics and precision medicine enabling personalized treatment approaches and targeted therapeutic interventions Technological Advancements: Integration of next-generation sequencing technologies, artificial intelligence, and machine learning enhancing accuracy, speed, and analytical capabilities in genomic analysis Regulatory Support: Improvements in regulatory and reimbursement scenarios for whole genome sequencing facilitating broader clinical adoption and healthcare integration Regional Market Leadership and Emerging Growth North America commands the largest market share in 2025 with approximately 52.1% of the global market, driven by high research investments by pharmaceutical and biopharmaceutical companies, presence of leading whole genome sequencing providers, high awareness of genomic technologies, favorable government initiatives for genomics research, growing applications of NGS-based research, and favorable reimbursement scenarios. Asia-Pacific emerges as the fastest-growing region with a projected CAGR of 16.4% during 2025-2032, propelled by improving healthcare infrastructure, growing population driving healthcare demand, rising prevalence of genetic disorders, increasing government initiatives and funding supporting genomic research, and enhanced competitiveness in the global biotech market through countries like China, Japan, India, and Singapore. Europe represents a significant market, supported by advanced healthcare systems, strong research infrastructure, growing demand for personalized medicine applications, and presence of leading genomics companies with emphasis on innovation and clinical excellence. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global whole genome sequencing market features an innovative competitive ecosystem comprising specialized genomics companies, biotechnology firms, pharmaceutical companies, and integrated healthcare technology providers. This diverse landscape fosters rapid technological advancement through sophisticated sequencing platform development and comprehensive bioinformatics solution integration. Industry leaders are implementing integrated genomic solutions that combine advanced sequencing technologies with comprehensive data analysis capabilities and clinical interpretation services. Companies are pursuing strategic partnerships and acquisitions while addressing scalability and data management challenges across different genomic applications. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global whole genome sequencing market include Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), MGI Tech Co., Ltd. (China), and Beijing Genomics Institute (BGI) (China). These companies are focusing on strategies such as advanced sequencing technology development, comprehensive bioinformatics platform integration, clinical application expansion, strategic partnerships and acquisitions, and geographic expansion into emerging markets to strengthen their market position. Latest Industry Developments Recent market developments include: Precision Medicine Integration: Enhanced integration of whole genome sequencing with precision medicine applications enabling personalized treatment selection and therapeutic monitoring across diverse clinical specialties AI-Powered Analytics: Implementation of artificial intelligence and machine learning technologies improving genomic data interpretation, variant analysis, and clinical decision support capabilities Clinical Application Expansion: Strategic expansion of whole genome sequencing applications into new clinical areas including oncology, rare diseases, pharmacogenomics, and reproductive health Market Challenges and Opportunities While the market shows strong growth potential, it faces challenges including complex data management and storage requirements, need for specialized bioinformatics expertise, regulatory compliance across different jurisdictions, ethical considerations in genetic testing, and integration challenges with existing healthcare systems. However, significant opportunities exist in expanding precision medicine applications, growing healthcare expenditure in developing countries, increasing demand for personalized therapeutic approaches, emerging applications in digital health and telemedicine, rising adoption of preventive healthcare strategies, and growing need for comprehensive genetic analysis in complex diseases. The Pharmaceutical & Biotechnology Companies segment is projected to experience rapid growth during the forecast period, driven by increased R&D spending, rising incidence of genetic diseases, growing adoption of whole genome sequencing in drug development and genetic research, and extensive use of advanced sequencing technologies for cancer studies. Related Reports: Next Generation Sequencing Services Market DNA Sequencing Market Genomics Market by Technology, Product, Application - Global Forecast Pharmacogenomics Market by Technology, Application - Global Forecast About Meticulous Research We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact: Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- sales@ Our Website: with us on LinkedIn- Source: Logo: View original content: SOURCE Meticulous Market Research Pvt. Ltd. Sign in to access your portfolio